Efficacy and Safety Study of Gevokizumab to Treat Behcet's Disease Uveitis
| Status: | Terminated |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | November 2014 |
| End Date: | November 2015 |
A Randomized-Withdrawal, Double-Masked, Placebo-Controlled Study of the Efficacy and Safety of Gevokizumab in Treating Subjects With Behcet's Disease Uveitis
The objective of this study is to assess the efficacy and safety of gevokizumab in treating
Behcet's disease uveitis (BDU).
Behcet's disease uveitis (BDU).
Inclusion Criteria:
- Have characteristics of Behcet's disease consistent with International Criteria for
Behcet's disease
- Have a documented history of active uveitis with or without retinal vasculitis within
the past 12 months
- Best corrected visual acuity (BCVA) >= 20 ETDRS letters in both eyes at baseline
- Effective contraceptive measures
Exclusion Criteria:
- Infectious uveitis and masquerade syndromes
- End stage ocular disease
- History of allergic or anaphylactic reactions to monoclonal antibodies
- Active tuberculosis disease
- History of recurrent infection or predisposition to infection; active ocular
infection
- Pregnant or nursing women
Other protocol-defined inclusion/exclusion criteria may apply
We found this trial at
8
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials